Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and ...
RENO, Nev., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), producer of deep cycle lithium-ion batteries and industry leader in ...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
A research group at Germany's Fraunhofer Institute for Solar Energy Systems (Fraunhofer ISE) has shown that in situ gettering during the application of asymmetric configuration of n-type and p-type ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results